Cargando…

Recombinant cell-penetrating trichosanthin synergizes anti-PD-1 therapy in colorectal tumor

Alleviating immunosuppression of the tumor microenvironment is an important strategy to improve immune checkpoint therapy. It is an urgent but unmet need to develop adjuvant therapeutics for assisting the mainstay immunotherapies. Trichosanthin is an approved gynecology drug in China and its immunom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Meng, Liu, Ergang, Chen, Guihua, Tang, Yisi, Fang, Yuefei, He, Yang, Zhao, Pengfei, Zheng, Caihong, Muhitdinov, Bahtiyor, Huang, Yongzhuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092770/ https://www.ncbi.nlm.nih.gov/pubmed/37063415 http://dx.doi.org/10.7150/ijbs.81052

Ejemplares similares

Remodeling “cold” tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona
por: He, Yang, et al.
Publicado: (2022)

Advances on Delivery of Cytotoxic Enzymes as Anticancer Agents
por: Asrorov, Akmal M., et al.
Publicado: (2022)

The anti-cancerous activity of recombinant trichosanthin on prostate cancer cell PC3
por: Li, JinLong, et al.
Publicado: (2016)

Trichosanthin increases Granzyme B penetration into tumor cells by upregulation of CI-MPR on the cell surface
por: Li, Chunman, et al.
Publicado: (2017)

Anti-HIV Agent Trichosanthin Enhances the Capabilities of Chemokines to Stimulate Chemotaxis and G Protein Activation, and This Is Mediated through Interaction of Trichosanthin and Chemokine Receptors
por: Zhao, Jian, et al.
Publicado: (1999)

Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides
por: Lin, Tingting, et al.
Publicado: (2016)

Trichosanthin Promotes Anti-Tumor Immunity through Mediating Chemokines and Granzyme B Secretion in Hepatocellular Carcinoma
por: Wang, Kaifang, et al.
Publicado: (2023)

Trichosanthin inhibits cervical cancer by regulating oxidative stress-induced apoptosis
por: Zhu, Chenglu, et al.
Publicado: (2021)

A Sixty-Year Research and Development of Trichosanthin, a Ribosome-Inactivating Protein
por: Lu, Jia-Qi, et al.
Publicado: (2022)

Comparative Proteomic Analysis of Drug Trichosanthin Addition to BeWo Cell Line
por: Hu, Yajun, et al.
Publicado: (2022)

Magnetism-mediated targeting hyperthermia-immunotherapy in “cold” tumor with CSF1R inhibitor
por: Fang, Yuefei, et al.
Publicado: (2021)

Trichosanthin cooperates with Granzyme B to restrain tumor formation in tongue squamous cell carcinoma
por: Zhu, Zeyao, et al.
Publicado: (2021)

Trichosanthin Inhibits Breast Cancer Cell Proliferation in Both Cell Lines and Nude Mice by Promotion of Apoptosis
por: Fang, Evandro Fei, et al.
Publicado: (2012)

Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
por: Zhang, Meng, et al.
Publicado: (2017)

Trichosanthin enhances sensitivity of non-small cell lung cancer (NSCLC) TRAIL-resistance cells
por: You, Chengcheng, et al.
Publicado: (2018)

Structural and Functional Investigation and Pharmacological Mechanism of Trichosanthin, a Type 1 Ribosome-Inactivating Protein
por: Shi, Wei-Wei, et al.
Publicado: (2018)

Trichosanthin inhibits cell growth and metastasis by promoting pyroptosis in non-small cell lung cancer
por: Tan, Yan, et al.
Publicado: (2022)

Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy
por: Zhao, Pengfei, et al.
Publicado: (2018)

Tat-functionalized Ag-Fe(3)O(4) nano-composites as tissue-penetrating vehicles for tumor magnetic targeting and drug delivery
por: Liu, Ergang, et al.
Publicado: (2018)

Anti-tumor action of trichosanthin, a type 1 ribosome-inactivating protein, employed in traditional Chinese medicine: a mini review
por: Sha, Ou, et al.
Publicado: (2013)

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
por: Zhao, Mingxia, et al.
Publicado: (2019)

Anti-Invasive and Anti-Proliferative Synergism between Docetaxel and a Polynuclear Pd-Spermine Agent
por: Batista de Carvalho, Ana L. M., et al.
Publicado: (2016)

Structures of Eukaryotic Ribosomal Stalk Proteins and Its Complex with Trichosanthin, and Their Implications in Recruiting Ribosome-Inactivating Proteins to the Ribosomes
por: Choi, Andrew K. H., et al.
Publicado: (2015)

Trichosanthin suppresses the proliferation of glioma cells by inhibiting LGR5 expression and the Wnt/β-catenin signaling pathway
por: MIAO, JUNJIE, et al.
Publicado: (2015)

β-Catenin inhibition shapes tumor immunity and synergizes with immunotherapy in colorectal cancer
por: Wang, Caihong, et al.
Publicado: (2020)

PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy
por: Zheng, Yimin, et al.
Publicado: (2023)

Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer
por: Wang, Yue, et al.
Publicado: (2023)

The C-terminal fragment of the ribosomal P protein complexed to trichosanthin reveals the interaction between the ribosome-inactivating protein and the ribosome
por: Too, Priscilla Hiu-Mei, et al.
Publicado: (2009)

“Two-birds-one-stone” colon-targeted nanomedicine treats ulcerative colitis via remodeling immune microenvironment and anti-fibrosis
por: Zhang, Jiaxin, et al.
Publicado: (2022)

Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer
por: Catalano, Calogerina, et al.
Publicado: (2018)

High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model
por: Luchtel, Rebecca A., et al.
Publicado: (2020)

Interaction between trichosanthin, a ribosome-inactivating protein, and the ribosomal stalk protein P2 by chemical shift perturbation and mutagenesis analyses
por: Chan, Denise S.B., et al.
Publicado: (2007)

Trichosanthin enhances the antitumor effect of gemcitabine in non-small cell lung cancer via inhibition of the PI3K/AKT pathway
por: Tuya, Naren, et al.
Publicado: (2017)

BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC
por: Wang, Huijin, et al.
Publicado: (2022)

Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer
por: Zhang, Ning, et al.
Publicado: (2021)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR(T790M) mutation
por: Yin, Weimin, et al.
Publicado: (2020)

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
por: Yi, Ming, et al.
Publicado: (2021)

Genetically-engineered “all-in-one” vaccine platform for cancer immunotherapy
por: Wu, Aihua, et al.
Publicado: (2021)

ATP protects anti-PD-1/radiation-induced cardiac dysfunction by inhibiting anti-PD-1 exacerbated cardiomyocyte apoptosis, and improving autophagic flux
por: Wang, Jing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k3ugim6fhn2r6qme1grs205drc